Pronounce: knee-VOL-you-mab and hy-al-uron-i-dase
Classification: Monoclonal antibody (PD-1) and endoglycosidase combination
The immune system works by creating antibodies, which are proteins that attach to antigens found on the surface of a cell. The antibody “calls” the immune system to attack the cell it is attached to, causing the immune system to kill the cell. Monoclonal antibodies are created in a lab to attach to the antigens found on specific types of cancer cells. These antibodies can work in different ways, including stimulating the immune system to kill the cell, blocking cell growth, or other functions necessary for cell growth.
Nivolumab is a type of monoclonal antibody therapy that works to stimulate the immune system to kill cancer cells. T-cells are a type of white blood cell that are important to the normal functioning of the immune system. Nivolumab works as a form of immunotherapy by binding to the "programmed death receptor" (PD1) found on T-cells to stimulate your immune system to find and kill cancer cells.
Hyaluronidase is an endoglycosidase that helps your body absorb (take in) nivolumab.
Nivolumab and hyaluronidase-nvhy is given as a subcutaneous (SubQ, under the skin) injection in your thigh or abdomen (belly) over about 3 to 5 minutes. Each subsequent injection will alternate between different injection sites. This medication is given by a healthcare professional, often in a clinic or provider’s office.
Make sure your care team is aware of all medications (including prescription and over-the-counter), supplements, and vitamins you are taking. Steroids should be avoided while on immunotherapy unless directed by your care team.
Tell your care team if you have had or are planning to have an organ or stem cell transplant, or if you have had radiation therapy to your chest in the past.
Tell your care team about all your medical conditions, including those that are autoimmune (Crohn’s disease, lupus, rheumatoid arthritis, etc.), as these can get worse with immunotherapy. You should also notify your provider if you have had or plan on having an allogeneic stem cell transplant, as this medication can worsen a side effect of the transplant called graft-versus-host disease.
There are many things you can do to manage the side effects of nivolumab. Talk to your care team about these recommendations. They can help you decide what will work best for you. These are some of the most common or important side effects:
This medication stimulates your immune system. Your immune system can attack normal organs and tissues in your body, leading to serious or life-threatening complications. It is important to notify your healthcare provider right away if you develop any of the following symptoms:
This medication can affect the normal levels of electrolytes (sodium, potassium, calcium, etc.) in your body. Your levels will be monitored with blood tests. If your levels become too low, your care team may prescribe certain electrolytes to be given by IV or taken by mouth. Do not take any supplements without first talking with your care team.
Your healthcare provider can recommend medications and other strategies to help relieve pain.
Fatigue is very common during cancer treatment and is an overwhelming feeling of exhaustion that is not usually relieved by rest. While on cancer treatment, and for a period after, you may need to adjust your schedule to manage fatigue. Plan times to rest during the day and conserve energy for more important activities. Exercise can help combat fatigue; a simple daily walk with a friend can help. Talk to your healthcare team for helpful tips on dealing with this side effect.
Exposure of an unborn child to this medication could cause birth defects, so you should not become pregnant or father a child while on this medication. For women, effective birth control is necessary during treatment and for at least 5 months after your last dose. Men should talk with their provider about the use of birth control during and after treatment. Even if your menstrual cycle stops or you believe you are not producing sperm, you could still be fertile and conceive. You should not breastfeed while taking this medication or for 5 months after your last dose.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2025 Trustees of The University of Pennsylvania